Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck swung to a fourth-quarter profit as sales grew and even exceeded Wall Street’s estimates, boosted in part by the ...

Merck’s problems in China seem to be getting worse, raising questions about the company’s growth. Trouble with sales of Merck ...

The drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares.

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.

Merck has halted the phase 3 HYPERION trial of ... Winrevair garnered slightly disappointing sales of $149 million in the third quarter of 2024 but a recent survey by Leerink Partners of ...

Merck plans to stop a late-stage study testing ... 2025 Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates ...

Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck faces broader industry pressure as vaccine skeptic Robert F. Kennedy Jr. possibly next ...

KEYTRUDA currently accounts for 44.6% of Merck’s total revenue and the share is rapidly increasing: In the third quarter, KEYTRUDA sales increased 17.2% from the prior year while non-KEYTRUDA ...